We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Handheld Fluorescent Immunoassay Analyzer for Rapid POC Testing to Transform Clinical Diagnostics

By LabMedica International staff writers
Posted on 17 Jul 2023

An automated, compact, and affordable fluorescent Immunoassay (FIA) solution is designed to transform the landscape of clinical point-of-care (POC) diagnostics. More...

Anbio Biotechnology (Frankfurt, Germany) has launched the new AF-100S FIA Solution, a compact, handheld solution for point-of-care immunodiagnostic needs that delivers rapid, accurate, and reliable results. The innovative analyzer is capable of detecting a broad spectrum of analytes, such as hormones, enzymes, and infectious diseases, making it a versatile diagnostic tool. Its compact design, lasting battery life, and user-friendly interface make it a practical choice for diverse environments. Its high sensitivity and specificity guarantee that patients are provided accurate results.

The AF-100S employs fluorescently labeled antibodies or antigens to identify specific biomolecules in a patient's sample. When a sample is combined with these labeled antibodies or antigens, the biomolecule, if present, binds to these labeled molecules, creating a complex that releases a fluorescent signal. This signal is then measured and compared with a recognized standard to ascertain the biomolecule's concentration in the sample.

This small yet efficient FIA analyzer can perform up to 240 tests per hour, making it a good fit for high-volume settings. It is powered by a lithium battery that supports up to 800 tests per charge or offers 20 days of device standby time. Its user-friendly interface, shown on a large color touchscreen, simplifies operation. The compact size of the AF-100S, measuring just 195x100x70mm, makes it an optimal choice for various medical settings such as private clinics, urgent care centers, emergency departments, and ambulances.

"The Anbio AF-100S is set to transform the field of clinical diagnostics, empowering healthcare providers with a cost-effective and comprehensive solution," said Sa Jiang, Chief Marketing Officer at Anbio. "Our FIA solution is small, yet powerful point-of-care immunodiagnostic solution that provides rapid, accurate, and reliable results for a wide range of analytes to provide faster diagnosis and better prognosis to patients."

Related Links:
Anbio Biotechnology


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Multi-Chamber Washer-Disinfector
WD 390
New
Gold Member
Quantitative lmmunoassay Test Menu
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.